PHA-739358 for Treatment of Hormone Refractory Prostate Cancer
Status:
Completed
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
To assess the antitumor activity of PHA-739358 administered as IV infusion according to two
different dose schedules in metastatic HRPC patients progressing on standard, docetaxel-based
1st-line chemotherapy for HRPC based on PSA response, and to select the best dose schedule
for further investigation.